Nevirapina Farmoz (Nevirapine)

Nevirapine, the active ingredient in Nevirapina Farmoz, is a non-nucleoside reverse transcriptase inhibitor presented as an oral tablet for oral use. It is used in combination antiretroviral therapy to treat HIV-1 infection in adults and adolescents. The medication is indicated for patients requiring a potent NNRTI component within a multidrug regimen.

GNH USA supplies Nevirapina Farmoz as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality and regulatory compliance across global markets.

Nevirapina Farmoz is an NNRTI used in the management of HIV-1 infection as part of combination antiretroviral therapy. - HIV-1 infection (treatment‑naïve adults): reduces viral load when combined with other antiretrovirals. - HIV-1 infection (treatment‑experienced adults): provides an alternative NNRTI option in salvage regimens. - Pediatric HIV-1 infection (≥2 years): used as part of age‑appropriate combination therapy.

Nevirapine may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Rash: mild to moderate skin eruptions. - Nausea: occasional gastrointestinal discomfort. - Fatigue: general feeling of tiredness. - Headache: transient cranial pain. - Insomnia: difficulty sleeping. - Elevated liver enzymes: mild hepatic enzyme changes.

Serious or Rare Side Effects: - Stevens‑Johnson syndrome: severe skin reaction requiring immediate discontinuation. - Toxic epidermal necrolysis: life‑threatening skin detachment. - Hepatic failure: severe liver injury with jaundice. - Hypersensitivity reactions: including fever and eosinophilia. - Severe rash: extensive or bullous skin lesions. - Drug‑induced liver injury: marked transaminase elevations with clinical hepatitis.

When prescribing Nevirapina Farmoz, clinicians should consider several safety measures. - Liver function monitoring: assess baseline and periodic liver enzyme levels. - Skin reactions: discontinue the drug promptly if a severe rash or hypersensitivity develops. - Pregnancy considerations: avoid use during the first trimester due to potential hepatotoxicity. - Drug interaction review: evaluate concomitant medications that affect CYP enzymes. - Adherence counseling: ensure consistent dosing to minimize resistance development. - Store at ambient temperature: keep in the original pack, protect from moisture and light.

Nevirapina Farmoz can interact with other medicines, influencing efficacy or safety.

Major Interactions (Avoid): - Ritonavir‑boosted protease inhibitors: may increase nevirapine levels, raising hepatotoxicity risk. - St. John's Wort: can reduce nevirapine concentrations, compromising antiviral effect.

Moderate Interactions (Monitor Closely): - Efavirenz: additive central nervous system effects may occur. - Zidovudine: potential for increased bone marrow suppression. - CYP3A4 inducers (e.g., carbamazepine): may lower nevirapine plasma levels, reducing efficacy.